Research Article
Screening Optimization of Latent Tuberculosis Infection in Rheumatoid Arthritis Patients
Table 1
Baseline characteristics.
| | Characteristics | Positive TST and QFT-G | Positive TST and negative QFT-G | Negative TST and positive QFT-G | Negative TST and QFT-G | Total |
| | Avg. age (years) | 59.8 | 61.0 | 54.5 | 53.5 | 54.9 | | Std. deviation (years) | 13.1 | 11.2 | 13.8 | 11.3 | 12.2 | | Male, (%) | 3 (2%) | 1 (1%) | 1 (1%) | 12 (9%) | 17 (13%) | | Female, (%) | 12 (9%) | 7 (5%) | 26 (20%) | 70 (53%) | 115 (87%) | | Hispanic, (%) | 13 (10%) | 7 (5%) | 22 (17%) | 58 (44%) | 100 (76%) | | Non-Hispanic, (%) | 2 (2%) | 1 (1%) | 5 (4%) | 24 (18%) | 32 (24%) | | SS, (%) | 6 (5%) | 3 (2%) | 9 (7%) | 15 (11%) | 33 (25%) | | DMARDs, (%) | 13 (10%) | 7 (5%) | 25 (19%) | 75 (57%) | 120 (91%) | | BRMs, (%) | 7 (5%) | 2 (2%) | 12 (9%) | 28 (21%) | 49 (37%) | | No drugs, (%) | 1 (1%) | 0 (0%) | 1 (1%) | 6 (5%) | 8 (6%) | | DMARDs + SS + BRMs, (%) | 5 (4%) | 2 (2%) | 8 (6%) | 19 (14%) | 34 (26%) | | DMARDs + BRMs, (%) | 7 (5%) | 2 (2%) | 12 (9%) | 28 (21%) | 49 (37%) |
|
|
SS: history of significant steroid use, DMARDs: disease modifying antirheumatic drugs, BRMs: Biologic Response Modifiers, and : number.
|
